Engineered exosomes, methods of making engineered exosomes, and uses thereof

By introducing the TIMP3 gene into endothelial progenitor cells and utilizing the cell secretion mechanism to produce engineered exosomes, the problems of low TIMP3 loading efficiency and easy inactivation were solved, achieving efficient inhibition of MMP3 activity and improvement of vascular wall structural stability, providing a safe nanomedicine strategy.

CN122104596APending Publication Date: 2026-05-29NINGBO MEDICAL CENT LIHUILI HOSPITACL
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NINGBO MEDICAL CENT LIHUILI HOSPITACL
Filing Date
2026-01-22
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

In existing technologies, directly loading TIMP3 protein into exosomes is inefficient and easily inactivated, making it difficult to effectively deliver it to the target site to inhibit MMP3 activity, leading to instability in the vascular wall structure.

Method used

By introducing an expression vector carrying the human TIMP3 gene into endothelial progenitor cells, engineered exosomes are produced using the cells' own secretion mechanism, ensuring that TIMP3 is efficiently and stably encapsulated in the exosomes. The exosomes are then purified by differential centrifugation, enabling efficient delivery to the target site.

Benefits of technology

This approach achieves efficient loading and activity retention of TIMP3, significantly inhibits MMP3 activity, improves vascular wall structural stability, reduces systemic side effects, and provides a safe and efficient nanomedicine strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122104596A_ABST
    Figure CN122104596A_ABST
Patent Text Reader

Abstract

The application relates to the technical field of biological medicine, and discloses an engineered exosome, a preparation method and purposes thereof. The method comprises the following steps: introducing an exogenous nucleic acid coding a human TIMP3 protein into endothelial progenitor cells to construct engineered cells, and obtaining exosomes by separating and purifying the supernatant after culture. The engineered exosome is secreted by the endothelial progenitor cells and is efficiently loaded with the TIMP3, and has both cell homing characteristics and protease inhibition functions. The exosome can significantly inhibit matrix metalloproteinase 3 (MMP3) activity, reduce extracellular matrix degradation, and improve the structural stability of a blood vessel wall. The application provides a novel and efficient cell-free delivery strategy for treating aortic dissection, aneurysm and other vascular remodeling diseases.
Need to check novelty before this filing date? Find Prior Art